Da Volterra Presented Highly Convincing Results of Pre-clinical Studies at ASM 2016 : DAV132 Prevents CDI

Da Volterra Presented Highly Convincing Results of Pre-clinical Studies at ASM 2016 : DAV132 Prevents CDI


Back to news page

Da Volterra Presented Highly Convincing Results of Pre-clinical Studies at ASM 2016 : DAV132 Prevents CDI

Professor Antoine Andremont, founder of Da Volterra, presented a poster at ASM in Boston last month highlighing exciting pre-clinical data. Our product, DAV132 successfully protected hamsters from moxifloxacin, clindamycin, and ceftriaxone induced Clostridium difficile infections.  This study clearly shows that DAV132 constitutes the first preventive strategy that can potentially protect against CDI when applied concomitantly with diverse causative antibiotic treatments. The development of this promising strategy for the prevention of CDI in humans is ongoing.

For more details on this ground-breaking therapy please see our poster and visit our webpage for details on the human strategy.